A detailed history of Octagon Capital Advisors LP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 12,171,513 shares of NUVB stock, worth $35.9 Million. This represents 6.76% of its overall portfolio holdings.

Number of Shares
12,171,513
Previous 431,600 2720.09%
Holding current value
$35.9 Million
Previous $1.26 Million 2121.75%
% of portfolio
6.76%
Previous 0.29%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.3 - $3.83 $27 Million - $45 Million
11,739,913 Added 2720.09%
12,171,513 $28 Million
Q2 2024

Aug 14, 2024

SELL
$2.58 - $3.69 $2.43 Million - $3.48 Million
-943,270 Reduced 68.61%
431,600 $1.26 Million
Q1 2024

May 15, 2024

BUY
$1.46 - $3.97 $547,310 - $1.49 Million
374,870 Added 37.49%
1,374,870 $5 Million
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.53 $960,000 - $1.53 Million
1,000,000 New
1,000,000 $1.51 Million

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $641M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.